CN113150109A - 密封蛋白-6特异性免疫受体和t细胞表位 - Google Patents

密封蛋白-6特异性免疫受体和t细胞表位 Download PDF

Info

Publication number
CN113150109A
CN113150109A CN202110278993.9A CN202110278993A CN113150109A CN 113150109 A CN113150109 A CN 113150109A CN 202110278993 A CN202110278993 A CN 202110278993A CN 113150109 A CN113150109 A CN 113150109A
Authority
CN
China
Prior art keywords
cell
cells
cell receptor
peptide
cldn6
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110278993.9A
Other languages
English (en)
Chinese (zh)
Inventor
尤格·萨因
欧兹兰·图勒茨
皮特拉·西蒙
塔纳·奥莫科科
霍尔戈尔·霍夫
拉尔夫-霍尔戈尔·沃斯
安德里亚·布莱特克洛伊茨
凯思琳·霍博姆
卡罗利娜·安娜·姆罗兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Byrne Technology Cell & Gene Therapy Co ltd
TRON Translationale Onkologie an der Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz gGmbH
Astellas Pharma Inc
Original Assignee
Byrne Technology Cell & Gene Therapy Co ltd
Ganymed Pharmaceuticals GmbH
TRON Translationale Onkologie an der Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz gGmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52745896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN113150109(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Byrne Technology Cell & Gene Therapy Co ltd, Ganymed Pharmaceuticals GmbH, TRON Translationale Onkologie an der Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz gGmbH filed Critical Byrne Technology Cell & Gene Therapy Co ltd
Publication of CN113150109A publication Critical patent/CN113150109A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
CN202110278993.9A 2014-04-01 2015-03-30 密封蛋白-6特异性免疫受体和t细胞表位 Pending CN113150109A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EPPCT/EP2014/000868 2014-04-01
EP2014000868 2014-04-01
EP2014072864 2014-10-24
EPPCT/EP2014/072864 2014-10-24
CN201580017607.3A CN106459165B (zh) 2014-04-01 2015-03-30 密封蛋白-6特异性免疫受体和t细胞表位

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580017607.3A Division CN106459165B (zh) 2014-04-01 2015-03-30 密封蛋白-6特异性免疫受体和t细胞表位

Publications (1)

Publication Number Publication Date
CN113150109A true CN113150109A (zh) 2021-07-23

Family

ID=52745896

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202110279207.7A Pending CN113150110A (zh) 2014-04-01 2015-03-30 密封蛋白-6特异性免疫受体和t细胞表位
CN201580017607.3A Active CN106459165B (zh) 2014-04-01 2015-03-30 密封蛋白-6特异性免疫受体和t细胞表位
CN202110278993.9A Pending CN113150109A (zh) 2014-04-01 2015-03-30 密封蛋白-6特异性免疫受体和t细胞表位

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN202110279207.7A Pending CN113150110A (zh) 2014-04-01 2015-03-30 密封蛋白-6特异性免疫受体和t细胞表位
CN201580017607.3A Active CN106459165B (zh) 2014-04-01 2015-03-30 密封蛋白-6特异性免疫受体和t细胞表位

Country Status (21)

Country Link
US (3) US10370423B2 (enExample)
EP (3) EP3126381B2 (enExample)
JP (3) JP6726656B2 (enExample)
CN (3) CN113150110A (enExample)
AU (3) AU2015239683B2 (enExample)
CA (1) CA2942459C (enExample)
CY (1) CY1121539T1 (enExample)
DK (3) DK3126381T4 (enExample)
ES (3) ES2717530T5 (enExample)
FI (1) FI3708579T3 (enExample)
HR (2) HRP20240926T1 (enExample)
HU (3) HUE044515T2 (enExample)
LT (2) LT3126381T (enExample)
ME (1) ME03407B (enExample)
MX (1) MX376026B (enExample)
PL (3) PL3708579T3 (enExample)
PT (3) PT3708579T (enExample)
RS (2) RS58627B2 (enExample)
SI (3) SI3708579T1 (enExample)
SM (1) SMT201900262T1 (enExample)
WO (1) WO2015150327A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024165057A1 (en) * 2023-02-07 2024-08-15 LaNova Medicines Limited Antibodies and antibody-drug conjugates targeting claudin 6

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ716587A (en) * 2009-11-11 2017-10-27 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (cldn6)
KR101935088B1 (ko) 2012-08-24 2019-01-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
US10053511B2 (en) 2013-11-06 2018-08-21 Abbvie Stemcentrx Llc Anti-claudin antibodies and methods of use
MA40921A (fr) * 2014-11-05 2017-09-12 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
EP3808770B1 (en) * 2014-11-14 2025-10-29 The U.S.A. as represented by the Secretary, Department of Health and Human Services Anti-thyroglobulin t cell receptors
CN106146666B (zh) * 2015-03-26 2019-09-06 科济生物医药（上海）有限公司 靶向cldn6的免疫效应细胞及其制备方法和应用
WO2016180468A1 (en) 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
WO2016180467A1 (en) 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
DK3298033T4 (da) 2015-05-18 2023-10-02 Tcr2 Therapeutics Inc Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner
EP3932428A1 (en) 2015-05-21 2022-01-05 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201607534D0 (en) 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201602918D0 (en) * 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
MA55153A (fr) 2016-02-19 2021-09-29 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre le lymphome non hodgkinien et d'autres cancers
AU2017276706B2 (en) * 2016-06-07 2024-08-15 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Chimeric antigen receptor and CAR-T cells that bind BCMA
IL299099B2 (en) 2016-06-27 2025-07-01 Univ California Cancer treatment combinations
WO2018011421A1 (en) 2016-07-14 2018-01-18 Genmab A/S Multispecific antibodies against cd40 and cd137
CA3036745A1 (en) * 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
BR112019011277A2 (pt) 2016-12-02 2019-10-22 University Of Southern California polinucleotídeo, sistema de expressão recombinante, vetor, polipeptídeo, célula recombinante, polipeptídeo de receptor imune sintético isolado ou heterodímero de polipeptídeo, célula efetora imune ou célula-tronco, população de células imunes ou efetoras, métodos de fabricação de uma célula efetora imune que expressa sir, de geração de uma população de células modificadas por rna, de fornecimento de imunidade antidoença e de tratamento ou prevenção de uma doença, composição, uso ou método, kit, e, sequência de aminoácidos.
SG11201908527SA (en) * 2017-03-15 2019-10-30 Hutchinson Fred Cancer Res High affinity mage-a1-specific tcrs and uses thereof
US20210122831A1 (en) * 2017-03-27 2021-04-29 Noile-Immune Biotech, Inc. Chimeric antigen receptor
CN111406067B (zh) 2017-08-04 2022-11-08 健玛保 与pd-l1和cd137结合的结合剂及其用途
NO20210351A1 (en) * 2017-09-18 2021-03-18 Univ California Claudin6 antibodies and methods of treating cancer
CN117003875A (zh) 2017-09-29 2023-11-07 第一三共株式会社 抗体或其功能性片段、多核苷酸、表达载体、宿主细胞、糖链重构抗体、药物组合物、应用
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
KR20210124959A (ko) 2018-11-06 2021-10-15 젠맵 에이/에스 항체 제제
CA3119188A1 (en) * 2018-11-09 2020-05-14 Fred Hutchinson Cancer Research Center T cell receptors specific for mesothelin and their use in immunotherapy
AU2019394940A1 (en) * 2018-12-05 2021-06-24 Genentech, Inc. Diagnostic methods and compositions for cancer immunotherapy
RS66364B1 (sr) * 2019-02-08 2025-01-31 Biontech Cell & Gene Therapies Gmbh Ćelije modifikovane himerinim antigenskim receptorima za lečenje kancera koji eksprimiraju cldn6
CN114174829A (zh) * 2019-03-01 2022-03-11 磨石生物公司 T细胞受体的选择
SI3941946T1 (sl) 2019-03-20 2025-09-30 The Regents Of The University Of California Protitelesa proti klavdinu-6 in konjugati zdravil
WO2021129927A1 (en) * 2019-12-23 2021-07-01 Biontech Cell & Gene Therapies Gmbh Treatment with immune effector cells engineered to express an antigen receptor
US20230087164A1 (en) 2020-02-04 2023-03-23 Genmab A/S Antibodies for use in therapy
MX2023005386A (es) 2020-11-11 2023-05-23 BioNTech SE Anticuerpos monoclonales dirigidos contra la proteina de muerte programada-1 y su uso en medicina.
US20240216427A1 (en) * 2020-12-30 2024-07-04 St. Jude Children's Research Hospital, Inc. Chimeric antigen receptors targeting splice variants of the extracellular matrix proteins tenascin c (tnc) and procollagen 11a1 (col11a1)
IL309319A (en) 2021-06-21 2024-02-01 Genmab As Combined dosage regimen CD137 and PD-L1 binding agents
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
AU2022337286A1 (en) * 2021-09-03 2024-02-29 Novarock Biotherapeutics, Ltd. Bispecific binding proteins that bind cd137 and a tumor associated antigen
US20250002600A1 (en) 2021-10-06 2025-01-02 Genmab A/S Multispecific binding agents against pd-l1 and cd137 in combination therapy
EP4412714A1 (en) 2021-10-06 2024-08-14 Genmab A/S Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers
CA3234897A1 (en) * 2021-10-14 2023-04-20 Kunle Odunsi Compositions and methods for use of recombinant t cell receptors against claudin 6
CA3252821A1 (en) 2022-05-12 2023-11-16 BioNTech SE LIAISON AGENTS CAPABLE OF BINDING TO CD27 IN POLYTHERAPY
US11932693B2 (en) 2022-05-12 2024-03-19 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
JP2025516631A (ja) 2022-05-12 2025-05-30 ジェンマブ エー／エス 併用療法においてｃｄ２７に結合する能力を有する結合剤
CN115232207B (zh) * 2022-05-19 2023-06-13 河南大学 抗体-溶菌素（SM-ScFv-Fc-Ly）在治疗变形链球菌感染中的应用
WO2024209072A1 (en) 2023-04-06 2024-10-10 Genmab A/S Multispecific binding agents against pd-l1 and cd137 for treating cancer
US12403202B2 (en) 2023-05-25 2025-09-02 The Regents Of The University Of California Dosage of claudin-6 conjugates for cancer treatment
WO2025114541A1 (en) 2023-11-30 2025-06-05 Genmab A/S Antibodies capable of binding to ox40 in combination therapy
WO2025184170A1 (en) 2024-02-27 2025-09-04 Overt Bio, Inc. Methods and compositions for improving t cell function in an immunosuppressive environment
CN118812714B (zh) * 2024-08-21 2025-05-27 广州百吉生物制药有限公司 一种紧密连接蛋白抗体b3及其应用
CN119320451B (zh) * 2024-08-21 2025-05-16 百吉生物医药(广州)股份有限公司 一种紧密连接蛋白抗体d03及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008114733A1 (ja) * 2007-03-16 2008-09-25 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-4抗体
CN101316610A (zh) * 2005-09-22 2008-12-03 艾润·R·科恩 T细胞受体恒定区的免疫原性片段及其衍生的肽
WO2011130346A1 (en) * 2010-04-13 2011-10-20 Sigma-Aldrich Co. Methods for generating endogenously tagged protein
CN102325885A (zh) * 2009-02-20 2012-01-18 加尼梅德药物公司 用于癌症诊断和治疗的方法和组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
WO1997024447A1 (en) 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7435596B2 (en) * 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
EP2103628A4 (en) * 2006-12-14 2012-02-22 Forerunner Pharma Res Co Ltd MONOCLONAL ANTIBODY ANTI-CLAUDIN 3, AND TREATMENT AND DIAGNOSIS OF CANCER USING SUCH ANTIBODY
SG187457A1 (en) * 2008-01-11 2013-02-28 Univ Tokyo Anti-cldn6 antibody
EP2322555A1 (en) * 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (CLDN6)
NZ716587A (en) * 2009-11-11 2017-10-27 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (cldn6)
EP2547695B1 (en) * 2010-03-16 2018-05-09 Biontech Protein Therapeutics GmbH Tumor vaccination involving a humoral immune response against self-protein cldn18.2
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
ES2754394T3 (es) * 2010-09-08 2020-04-17 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Receptores de antígenos quiméricos con una región bisagra optimizada
NZ724296A (en) * 2011-05-13 2020-05-29 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
CN104159909A (zh) 2012-02-22 2014-11-19 宾夕法尼亚大学董事会 产生用于癌症治疗的t细胞持续性群体的组合物和方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101316610A (zh) * 2005-09-22 2008-12-03 艾润·R·科恩 T细胞受体恒定区的免疫原性片段及其衍生的肽
WO2008114733A1 (ja) * 2007-03-16 2008-09-25 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-4抗体
EP2138576A1 (en) * 2007-03-16 2009-12-30 Kyowa Hakko Kirin Co., Ltd. Anti-claudin-4 antibody
CN102325885A (zh) * 2009-02-20 2012-01-18 加尼梅德药物公司 用于癌症诊断和治疗的方法和组合物
WO2011130346A1 (en) * 2010-04-13 2011-10-20 Sigma-Aldrich Co. Methods for generating endogenously tagged protein

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024165057A1 (en) * 2023-02-07 2024-08-15 LaNova Medicines Limited Antibodies and antibody-drug conjugates targeting claudin 6
US12180276B2 (en) 2023-02-07 2024-12-31 LaNova Medicines Limited Antibodies and antibody-drug conjugates targeting claudin 6

Also Published As

Publication number Publication date
JP2020096630A (ja) 2020-06-25
WO2015150327A1 (en) 2015-10-08
EP3126381A1 (en) 2017-02-08
AU2021203528B2 (en) 2022-10-13
CA2942459A1 (en) 2015-10-08
MX376026B (es) 2025-03-07
RS58627B1 (sr) 2019-05-31
AU2015239683B2 (en) 2019-08-22
JP6985440B2 (ja) 2021-12-22
EP3708579A1 (en) 2020-09-16
CN106459165A (zh) 2017-02-22
ES2717530T5 (es) 2022-05-06
ES2982838T3 (es) 2024-10-17
SI3126381T2 (sl) 2022-05-31
HRP20190472T1 (hr) 2019-06-14
LT3708579T (lt) 2024-07-25
RS58627B2 (sr) 2022-06-30
ES2717530T3 (es) 2019-06-21
US11345731B2 (en) 2022-05-31
HRP20190472T4 (hr) 2022-06-24
ME03407B (me) 2020-01-20
SMT201900262T1 (it) 2019-07-11
US20170015720A1 (en) 2017-01-19
JP7451858B2 (ja) 2024-03-19
EP3514172A1 (en) 2019-07-24
EP3126381B1 (en) 2019-01-16
PT3514172T (pt) 2020-04-21
HUE067504T2 (hu) 2024-10-28
AU2015239683A1 (en) 2016-09-08
CN106459165B (zh) 2021-04-20
SI3126381T1 (sl) 2019-07-31
EP3514172B1 (en) 2020-03-11
DK3708579T3 (da) 2024-07-22
EP3126381B2 (en) 2022-02-16
HUE044515T2 (hu) 2019-10-28
JP6726656B2 (ja) 2020-07-22
BR112016022727A2 (pt) 2017-10-31
DK3126381T4 (da) 2022-04-04
NZ723544A (en) 2021-10-29
AU2019210582A1 (en) 2019-08-22
AU2019210582B2 (en) 2021-03-04
MX2016012713A (es) 2018-03-01
CA2942459C (en) 2023-03-07
PT3126381T (pt) 2019-04-18
US10370423B2 (en) 2019-08-06
JP2017518762A (ja) 2017-07-13
ES2784537T3 (es) 2020-09-28
BR112016022727A8 (pt) 2018-12-04
CY1121539T1 (el) 2020-05-29
PL3126381T3 (pl) 2019-09-30
CN113150110A (zh) 2021-07-23
DK3126381T3 (en) 2019-04-15
RS65784B1 (sr) 2024-08-30
AU2021203528A1 (en) 2021-07-01
PL3126381T5 (pl) 2022-05-23
LT3126381T (lt) 2019-05-27
SI3708579T1 (sl) 2024-09-30
HRP20240926T1 (hr) 2024-10-11
DK3514172T3 (da) 2020-04-06
PL3514172T3 (pl) 2020-07-27
PT3708579T (pt) 2024-07-17
SI3514172T1 (sl) 2020-07-31
PL3708579T3 (pl) 2024-08-05
US20220306711A1 (en) 2022-09-29
US20190389920A1 (en) 2019-12-26
EP3708579B1 (en) 2024-05-01
HUE050355T2 (hu) 2020-12-28
FI3708579T3 (fi) 2024-07-16
JP2022046462A (ja) 2022-03-23

Similar Documents

Publication Publication Date Title
JP7451858B2 (ja) クローディン６特異的免疫受容体およびｔ細胞エピトープ
JP7194230B2 (ja) クローディン－１８．２－特異的免疫受容体およびｔ細胞エピトープ
HK40055485A (en) Claudin-6-specific immunoreceptors and t cell epitopes
HK40048260A (en) Claudin-6-specific immunoreceptors and t cell epitopes
CN115109141B (zh) 闭合蛋白-18.2特异性免疫受体和t细胞表位
HK40080457A (en) Claudin-18.2-specific immunoreceptors and t cell epitopes
HK40049189A (en) Claudin-18.2-specific immunoreceptors and t cell epitopes
HK40049189B (en) Claudin-18.2-specific immunoreceptors and t cell epitopes
HK40026429B (en) Claudin-6-specific immunoreceptors and t cell epitopes
HK40026429A (en) Claudin-6-specific immunoreceptors and t cell epitopes
HK40011474B (en) Claudin-6-specific immunoreceptors and t cell epitopes
HK40011474A (en) Claudin-6-specific immunoreceptors and t cell epitopes
HK1247815B (en) Claudin-18.2-specific immunoreceptors and t cell epitopes
HK1250331B (en) Claudin-18.2-specific immunoreceptors and t cell epitopes
HK1246802A1 (en) Claudin-6-specific immunoreceptors and t cell epitopes
HK1246802B (en) Claudin-6-specific immunoreceptors and t cell epitopes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40048260

Country of ref document: HK

CB02 Change of applicant information

Country or region after: Germany

Address after: Mainz, Germany

Applicant after: Byrne Technology Cell & Gene Therapy Co.,Ltd.

Country or region after: De Guo

Applicant after: TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITAT MAINZ GE

Country or region after: De Guo

Applicant after: Ganimead Pharmaceutical Co.,Ltd.

Address before: Mainz, Germany

Applicant before: Byrne Technology Cell & Gene Therapy Co.,Ltd.

Country or region before: Germany

Applicant before: TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITAT MAINZ GE

Country or region before: De Guo

Applicant before: GANYMED PHARMACEUTICALS AG

CB02 Change of applicant information
TA01 Transfer of patent application right

Effective date of registration: 20240301

Address after: Mainz, Germany

Applicant after: Byrne Technology Cell & Gene Therapy Co.,Ltd.

Country or region after: Germany

Applicant after: TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITAT MAINZ GE

Applicant after: ASTELLAS PHARMA Inc.

Country or region after: Japan

Address before: Mainz, Germany

Applicant before: Byrne Technology Cell & Gene Therapy Co.,Ltd.

Country or region before: Germany

Applicant before: TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITAT MAINZ GE

Country or region before: De Guo

Applicant before: Ganimead Pharmaceutical Co.,Ltd.

TA01 Transfer of patent application right